Comparison
6q Terminal Deletion Syndrome C4304514 vs 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
Clinical comparison between 6Q Terminal Deletion Syndrome and 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete CN042980 for differential diagnosis and treatment planning.
6q Terminal Deletion Syndrome C4304514
A chromosomal disorder involving deletion of genetic material at the end of chromosome 6, leading to developmental delays and variable physical features.
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
A rare enzyme deficiency affecting hormone production, leading to low sex hormones and elevated blood pressure. Lifelong hormone replacement therapy is typically needed. Ongoing medical monitoring helps manage associated health concerns.
6 comparison axes
Onset
6q Terminal Deletion Syndrome C4304514
0-0
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
0-null
Onset patterns differ
Severity
6q Terminal Deletion Syndrome C4304514
severe
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
severe
Different severity levels
Chronic
6q Terminal Deletion Syndrome C4304514
Chronic
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
Chronic
Differing course
Communicable
6q Terminal Deletion Syndrome C4304514
No
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
No
Different transmission
Body System
6q Terminal Deletion Syndrome C4304514
congenital
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
endocrine
Same/different system
Category
6q Terminal Deletion Syndrome C4304514
genetic
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
endocrine
Different category
Bottom line
6q-terminal-deletion-syndrome-C4304514 and 17-alpha-hydroxylase-17-20-lyase-deficiency-combined-complete-CN042980 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 6q Terminal Deletion Syndrome C4304514 | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 | Discriminating power |
|---|---|---|---|
| Developmental pattern | Developmental delay and variable physical features are described. | The main picture is hormone deficiency and hypertension, not a chromosomal syndrome. | High |
| Blood pressure | Hypertension is not established as a defining feature. | Elevated blood pressure is a recognized clinical concern. | High |
| Sexual development | Specific effects on puberty are not established from the supplied data. | Low sex hormones may affect puberty and sexual development. | Moderate |
When to favor each condition
Choose 6q Terminal Deletion Syndrome C4304514 when
Testing confirms a terminal 6q deletion
This supports the chromosomal diagnosis rather than the enzyme deficiency.
High
Congenital developmental delay with variable features
This fits the supplied description, but genetic confirmation is required.
Moderate
No steroid-enzyme pattern is identified
This makes the endocrine diagnosis less likely but does not prove the deletion.
Moderate
Choose 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 when
Low sex hormones occur with hypertension
This matches the described enzyme deficiency and needs specialist confirmation.
High
Genetic testing supports CYP17A1-related deficiency
A confirmed relevant variant directly favors the endocrine diagnosis.
High
Lifelong hormone replacement is being considered
This is consistent with typical care, but treatment must be individualized.
Moderate
How key tests differ
| Test | 6q Terminal Deletion Syndrome C4304514 | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or karyotype | May show deletion of terminal 6q material. | That chromosomal deletion is not expected. | A confirmed deletion supports the left condition; its absence does not exclude all other diagnoses. |
| Steroid hormone profile | No specific steroid pattern is established here. | Results may suggest low sex steroids and mineralocorticoid excess. | An endocrinologist should interpret the pattern; no cutoff is supplied. |
| Blood pressure measurement | No characteristic blood-pressure result is established. | Hypertension may be present. | Elevated pressure raises concern for the right condition but is not diagnostic alone. |
Prognosis comparison
6q Terminal Deletion Syndrome C4304514
- Outcome
- Chronic and potentially severe, with variable developmental impact.
- Factors
- Deletion extent and associated features are incompletely specified here.
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
- Outcome
- Chronic endocrine disease often requiring lifelong hormone care and pressure monitoring.
- Factors
- Hormone balance, blood pressure, and specialist follow-up influence course.
Time frame: Lifelong; exact outcomes are not established by the supplied data.
Cause, recognition, associated anomalies, and individualized care matter.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental impairment | Delays and functional limitations may occur. Not the defining complication in the supplied description. Severity varies, so developmental assessment is needed. |
| Blood-pressure-related harm | Not established as characteristic. Hypertension may require ongoing monitoring. Specific complication rates are not supplied. |
| Hormone-related problems | Not described as a steroid-enzyme disorder. Low sex hormones and replacement needs are typical concerns. Doses and exact risks cannot be inferred from these data. |
Patient education highlights
- HighDifferent causes
One condition is a chromosome deletion; the other is a steroid enzyme deficiency.
- HighNot contagious
Neither condition spreads from person to person.
- MediumSpecialist interpretation
Genetics or endocrinology should interpret results and plan monitoring.